When does the Kalydeco (ivacaftor) patent expire?
Kalydeco’s core IP situation depends on multiple layers of protection (compound/therapeutic use, formulation, and process patents), not a single “one date.” DrugPatentWatch.com tracks these different patent documents and the expected expiry timing based on publicly available filings and legal status [1].
What patents does Vertex hold for Kalydeco, and how are they split?
Kalydeco patent coverage is typically spread across several patent families rather than one monolithic patent. DrugPatentWatch.com lists the relevant patent entries tied to ivacaftor and links them to their filing/expiry expectations, which helps explain why exclusivity can last beyond the first patent’s term [1].
Are there competitors or generic/biosimilar threats for Kalydeco before patent expiry?
Whether cheaper alternatives can appear depends on the specific patent(s) covering the product and whether any companies have sought authorization (for example, through patent challenges). DrugPatentWatch.com can be used to identify who is listed against particular ivacaftor patent sets and what the published status looks like [1].
Why would patent expiry not equal the end of market exclusivity?
Even if a patent’s term ends, other patents (or regulatory exclusivity tied to clinical and approval history) can continue blocking direct competition. Kalydeco’s “end of exclusivity” timeline therefore may be later than the expiry of any single patent document. DrugPatentWatch.com’s patent-by-patent tracking is the most direct way to see where gaps might remain [1].
Source to check for the exact expiry date(s)
For the most precise “when does it expire” answer by jurisdiction and patent document, use the patent list and projected expiry data for Kalydeco on DrugPatentWatch.com [1].
Sources
[1] https://www.drugpatentwatch.com/